Abstract 2550, Dr Partick Wen - ASCO 2020. Journal of Clinical Oncology - published online 25 May 2020.
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.2550
Regards.
Abstract PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM)
Add to My Watchlist
What is My Watchlist?